Last Update: Jul 13, 2026 A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune-complex-mediated Membranoproliferative Glomerulonephritis (IC-MPGN) ClinicalTrials.gov Identifier: [NCT05755386](https://clinicaltrials.gov/ct2/show/NCT05755386) Novartis Reference Number:CLNP023B12302 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis. The purpose of this Phase III study is to evaluate the efficacy and safety of iptacopan compared to placebo (both administered in combination with standard of care) in participants (adults and adolescents aged 12-17 years) with idiopathic IC-MPGN. The study aims to demonstrate a reduction in proteinuria and improvement in estimated glomerular filtration rate (eGFR) in participants treated with iptacopan compared to placebo. Change in patient-reported fatigue will also be evaluated. Alternative complement pathway (AP) dysregulation is believed to underlie the clinical manifestations and progression of IC-MPGN. Upon completion of study treatment, participants will have the option to discontinue iptacopan treatment and enter a 30 day safety follow-up or continue iptacopan treatment by transitioning to an open label extension study (CLNP023B12001B; NCT03955445) and continue iptacopan treatment. Condition IC-MPGN Phase Phase3 Overall Status Recruiting Number of Participants106 Start Date Oct 02, 2023 Completion Date May 31, 2029 Gender All Age(s) 12 Years - 60 Years (Child, Adult) ## Interventions Drug ### iptacopan iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d) Drug ### Placebo Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d) ## Eligibility Criteria Inclusion Criteria: \* Male and female patients including adults (aged at least 18 years to ≤ 60 years) and adolescents (12 -17 years in non-EU countries at screening and 16-17 years in EU countries at screening). \* Diagnosis of idiopathic IC-MPGN as confirmed by kidney biopsy within 12 months prior to screening in adults and within 3 years of screening in adolescents (a biopsy report, review and confirmation by the Investigator is required). If such a biopsy is not available in an adult participant, this must be obtained at screening (performed and assessed locally for adults only). \* Prior to randomization, all participants must have been on a maximally recommended or tolerated dose of renin angiotensin system inhibitors (RASi), e.g an ACEi or ARB for at least 90 days (or as according to local guidelines). The doses of other drugs administered to reduce proteinuria and control the disease including mycophenolic acids (MPAs - mycophenolate mofetil or mycophenolate sodium), corticosteroids, SGLT2 inhibitors and mineralocorticoid receptor antagonists should be stable for at least 90 days prior to randomization \* UPCR ≥ 1.0 g/g (≥ 113 mg/mmol) sampled from the first morning void urine sample at Day -75 and Day -15 \* Estimated GFR (using the chronic kidney disease \\\[CKD\\\]-EPI formula for adult participants and modified Schwartz formula for adolescents aged 12 to 17 years) or measured GFR ≥ 30 ml/min/1.73m2 at screening and Day -15. \* Mandatory vaccination against Neisseria meningitidis and Streptococcus pneumoniae infection prior to the start of study treatment. If the participant has not been previously vaccinated, or if a booster is required, the vaccine should be given according to local regulations at least 2 weeks prior to the first administration of study treatment. If the study treatment has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment should be initiated in accordance with local standard of care. \* If not previously vaccinated, or if a booster is required, vaccination against Haemophilus influenzae infections should be given, if available and according to local regulations, at least 2 weeks prior to the first study treatment administration. Exclusion Criteria: \* Participants who have undergone cell or solid organ transplantation, including kidney transplantation. \* Participants diagnosed with secondary IC-MPGN including but not limited to any of the following conditions: \* Deposition of antigen-antibody immune complexes as a result of any chronic infections, including \* Hepatitis C virus (HCV) including HCV-associated mixed cryoglobulinemia, hepatitis B virus (HBV); \* Bacterial-endocarditis, infected ventriculo-atrial shunt, visceral abscesses, leprosy, meningococcal meningitis; chronic bacterial infections \* Protozoa/other infections- malaria, schistosomiasis, mycoplasma, leishmaniasis, filariasis, histroplasmosis Renal deposition of immune complexes as a result of a systemic autoimmune disease: \* Systemic lupus erythematosus (SLE) \* Sjögren syndrome \* Rheumatoid arthritis \* Mixed connective tissue disease Deposition of monoclonal immunoglobulins because of a monoclonal gammopathy due to plasma cell or B cell disorders. Monoclonal gammopathy of undetermined significance (MGUS) confirmed by the measurement of serum free light chains or other investigation as per local standard of care. Fibrillary glomerulonephritis \* Rapidly progressive crescentic glomerulonephritis defined as a 50% decline in the eGFR within 3 months with kidney biopsy findings of glomerular crescent formation seen in at least 50% of glomeruli on the most recent biopsy. \* Kidney biopsy showing interstitial fibrosis/tubular atrophy (IF/TA) of more than 50%. \* Participants with an active systemic bacterial, viral or fungal infection within 14 days prior to study treatment administration or the presence of fever ≥ 38°C (100.4°F) within 7 days prior to study treatment administration. \* A history of recurrent invasive infections caused by encapsulated organisms, e.g., Neisseria meningitidis and Streptococcus pneumoniae. \* The use of inhibitors of complement factors (e.g., Factor B, Factor D, complement 3 (C3) inhibitors, anti-Complement 5 (C5) antibodies, C5a receptor antagonists) within 3 months or 5 half-lives prior to the Screening visit. \* The use of immunosuppressants (except MPAs), cyclophosphamide or systemic corticosteroids at a dose \\>7.5 mg/day (or equivalent for a similar corticosteroid medication) within 90 days of study drug administration. \* The use of MPAs is not permitted within 90 days prior to randomization in India, as per the local health authority requirement. \* Acute post-infectious glomerulonephritis at screening, based upon the opinion of the investigator. \* Body mass index (BMI) \\>38 kg/m2 at screening and randomization. Body weight \\<35 kg at screening and randomization Argentina #### Novartis Investigative Site Recruiting Buenos Aires,W3400abh,Argentina #### Novartis Investigative Site Recruiting CABA,Buenos Aires,C1425agc,Argentina #### Novartis Investigative Site Recruiting CABA,Buenos Aires,C1425efd,Argentina #### Novartis Investigative Site Recruiting CABA,C1181ach,Argentina #### Novartis Investigative Site Recruiting Santa Fe,S3000epv,Argentina #### Novartis Investigative Site Recruiting Córdoba,Córdoba Province,X5000,Argentina Brazil #### Novartis Investigative Site Recruiting Belo Horizonte,Minas Gerais,30150-221,Brazil #### Novartis Investigative Site Recruiting Porto Alegre,Rio Grande do Sul,90035-074,Brazil #### Novartis Investigative Site Recruiting Botucatu,São Paulo,18618-970,Brazil #### Novartis Investigative Site Recruiting Santo André,São Paulo,09090-790,Brazil #### Novartis Investigative Site Recruiting São Paulo,São Paulo,04038-002,Brazil #### Novartis Investigative Site Recruiting São Paulo,São Paulo,05403-000,Brazil #### Novartis Investigative Site Recruiting Recife,Pernambuco,50740-900,Brazil #### Novartis Investigative Site Recruiting Sao Jose Rio Preto,São Paulo,15090-000,Brazil #### Novartis Investigative Site Recruiting Salvador,40323-010,Brazil #### Novartis Investigative Site Recruiting Natal,Rio Grande do Norte,59012 300,Brazil #### Novartis Investigative Site Recruiting Fortaleza,Ceará,60430 370,Brazil Canada #### Novartis Investigative Site Recruiting Montreal,Quebec,H3t 1c5,Canada #### Novartis Investigative Site Recruiting Etobicoke,Ontario,M9w 6v1,Canada #### Novartis Investigative Site Recruiting Toronto,Ontario,M5g 2c4,Canada #### Novartis Investigative Site Recruiting Montreal,Quebec,H2x 1r9,Canada #### Novartis Investigative Site Recruiting London,Ontario,N6a 5w9,Canada Czechia #### Novartis Investigative Site Recruiting Prague,128 08,Czechia Denmark #### Novartis Investigative Site Recruiting Aarhus N,8200,Denmark #### Novartis Investigative Site Recruiting Copenhagen,Dk-2100,Denmark France #### Novartis Investigative Site Recruiting Paris,75015,France #### Novartis Investigative Site Recruiting Toulouse,31054,France #### Novartis Investigative Site Recruiting Montpellier,34295,France #### Novartis Investigative Site Recruiting Marseille,13005,France #### Novartis Investigative Site Recruiting Rennes,35033,France Germany #### Novartis Investigative Site Recruiting Berlin,13353,Germany #### Novartis Investigative Site Recruiting Essen,45147,Germany #### Novartis Investigative Site Recruiting Mainz,55131,Germany #### Novartis Investigative Site Recruiting Munich,Bavaria,81377,Germany #### Novartis Investigative Site Recruiting Würzburg,Bavaria,97080,Germany #### Novartis Investigative Site Recruiting Dresden,Saxony,01307,Germany #### Novartis Investigative Site Recruiting Jena,Thuringia,07740,Germany #### Novartis Investigative Site Recruiting Hamburg,20246,Germany #### Novartis Investigative Site Recruiting Hanover,30625,Germany #### Novartis Investigative Site Recruiting Ulm,89081,Germany Greece #### Novartis Investigative Site Recruiting Chaïdári,124 62,Greece #### Novartis Investigative Site Recruiting Pátrai,265 04,Greece #### Novartis Investigative Site Recruiting Heraklion Crete.,715 00,Greece #### Novartis Investigative Site Recruiting Ioannina,455 00,Greece #### Novartis Investigative Site Recruiting Athens,115 27,Greece #### Novartis Investigative Site Recruiting Thessaloniki,54636,Greece #### Novartis Investigative Site Recruiting Thessaloniki,570 10,Greece India #### Novartis Investigative Site Recruiting Nagpur,Maharashtra,440015,India #### Novartis Investigative Site Recruiting Bangalore,Karnataka,560004,India #### Novartis Investigative Site Recruiting Pune,Maharashtra,411011,India #### Novartis Investigative Site Recruiting Hyderabad,Telangana,500082,India #### Novartis Investigative Site Recruiting New Delhi,National Capital Territory of Delhi,110029,India Israel #### Novartis Investigative Site Recruiting Haifa,3109601,Israel #### Novartis Investigative Site Recruiting Jerusalem,9103102,Israel #### Novartis Investigative Site Recruiting Petah Tikva,4920235,Israel Italy #### Novartis Investigative Site Recruiting Bari,BA,70124,Italy #### Novartis Investigative Site Recruiting Ranica,BG,24020,Italy #### Novartis Investigative Site Recruiting Brescia,BS,25123,Italy #### Novartis Investigative Site Recruiting Roma,RM,00165,Italy #### Novartis Investigative Site Recruiting Torino,TO,10126,Italy #### Novartis Investigative Site Recruiting Milan,MI,20122,Italy #### Novartis Investigative Site Recruiting Naples,80131,Italy Japan #### Novartis Investigative Site Recruiting Osaka,558-8558,Japan #### Novartis Investigative Site Recruiting Hachiōji,Tokyo,193-0998,Japan #### Novartis Investigative Site Recruiting Fuchū,Tokyo,1838561,Japan #### Novartis Investigative Site Recruiting Okayama,7008558,Japan #### Novartis Investigative Site Recruiting Toyoake,Aichi-ken,4701192,Japan Netherlands #### Novartis Investigative Site Recruiting Groningen,9713 gz,Netherlands Poland #### Novartis Investigative Site Recruiting Olsztyn,10-561,Poland #### Novartis Investigative Site Recruiting Bialystok,15-540,Poland #### Novartis Investigative Site Recruiting Krakow,30-688,Poland #### Novartis Investigative Site Recruiting Poznan,Greater Poland Voivodeship,60-355,Poland #### Novartis Investigative Site Recruiting Warsaw,02-006,Poland #### Novartis Investigative Site Recruiting Warsaw,02-097,Poland Slovakia #### Novartis Investigative Site Recruiting Martin,Slovakia,036 59,Slovakia #### Novartis Investigative Site Recruiting Košice,041 90,Slovakia #### Novartis Investigative Site Recruiting Banská Bystrica,975 17,Slovakia South Korea #### Novartis Investigative Site Recruiting Seoul,03722,South Korea #### Novartis Investigative Site Recruiting Seoul,Seoul,03080,South Korea Spain #### Novartis Investigative Site Recruiting Madrid,28040,Spain #### Novartis Investigative Site Recruiting Madrid,280796,Spain #### Novartis Investigative Site Recruiting Barcelona,08036,Spain #### Novartis Investigative Site Recruiting Madrid,28041,Spain #### Novartis Investigative Site Recruiting Pamplona,Navarre,31008,Spain #### Novartis Investigative Site Recruiting Almería,04009,Spain #### Novartis Investigative Site Recruiting Salamanca,37007,Spain #### Novartis Investigative Site Recruiting Barcelona,08035,Spain Switzerland #### Novartis Investigative Site Recruiting Bern,3010,Switzerland #### Novartis Investigative Site Recruiting Zurich,8091,Switzerland Taiwan #### Novartis Investigative Site Recruiting Kaohsiung City,81346,Taiwan Turkey (Türkiye) #### Novartis Investigative Site Recruiting Istanbul,Fatih,34093,Turkey (Türkiye) #### Novartis Investigative Site Recruiting Izmir,Karsiyaka,35575,Turkey (Türkiye) #### Novartis Investigative Site Recruiting Kayseri,Melikgazi,38039,Turkey (Türkiye) #### Novartis Investigative Site Recruiting Ankara,Yenimahalle,06500,Turkey (Türkiye) #### Novartis Investigative Site Recruiting Mersin,Yenisehir,33110,Turkey (Türkiye) #### Novartis Investigative Site Recruiting Köseköy,Kocaeli,41380,Turkey (Türkiye) United Kingdom #### Novartis Investigative Site Recruiting Cardiff,Cf14 4xw,United Kingdom #### Novartis Investigative Site Recruiting Belfast,Bt9 7ab,United Kingdom #### Novartis Investigative Site Recruiting London,Nw3 2qg,United Kingdom #### Novartis Investigative Site Recruiting Manchester,M13 9wl,United Kingdom #### Novartis Investigative Site Recruiting Salford,M6 8hd,United Kingdom #### Novartis Investigative Site Recruiting London,Wc1n 3jh,United Kingdom United States #### Childrens Hospital Colorado Recruiting Aurora,Colorado,80045,United States ###### Bradley Dixon ###### Kati Dugan Phone: [+1 720 777 1234]() Email: #### Col Uni Med Center New York Presby Recruiting New York,New York,10032,United States ###### Andrew S Bomback ###### Anup Pradhan Phone: [+1 212 304 5684]() Email: #### Ronald Reagan UCLA Medical Center Recruiting Los Angeles,California,90095,United States ###### Ahad Qureshi Email: ###### Lama Abdelnour #### Univ Cali Irvine ALS Neuromuscular Recruiting Orange,California,92868,United States ###### Nancy Ortega Email: ###### Ramy Hanna #### UCSF Recruiting San Francisco,California,94115,United States ###### Juan Espinoza Phone: [+1 415 476 5892]() Email: ###### Raymond Hsu #### Massachusetts General Hospital Recruiting Boston,Massachusetts,02114,United States ###### Andrew Cao Email: ###### Meghan Sise #### University of Minnesota Recruiting Minneapolis,Minnesota,55455,United States ###### Karen Omlung Phone: [+1 612 262 2750]() Email: ###### Nattawat Klomjit #### Baylor Scott and White Research Recruiting Temple,Texas,76502,United States ###### Mohanram Narayanan ###### Stephanie McMeen Phone: [+1 254 935 5838]() Email: #### Olive View UCLA Medical Center Recruiting Sylmar,California,91342,United States ###### Phuong-Chi Pham ###### Rosario Machicado Email: #### Nicklaus Childrens Hospital Recruiting Miami,Florida,33155,United States ###### Ana Paredes ###### Moya Chang Phone: [+1 786 624 4908]() Email: #### Univ of Pennsylvania Medical Center Recruiting Philadelphia,Pennsylvania,19104,United States ###### Cammy Truong Email: ###### Gaia Coppock #### University of Wisconsin Recruiting Madison,Wisconsin,53792,United States ###### Alana Quackenbush Phone: [+1 608 265 6020]() Email: ###### Sharon Bartosh #### University of New Mexico Recruiting Albuquerque,New Mexico,87131-0001,United States ###### Namita Singh ###### Susan L Tigert Phone: [+1 505 272 9992]() Email: #### University of Utah Recruiting Salt Lake City,Utah,84113,United States ###### Gabriella Gourdin Phone: [+1 415 515 8212]() Email: ###### Raoul Nelson #### Boston Univ School of Medicine Recruiting Boston,Massachusetts,02118,United States ###### Jean Francis ###### Kemberlie Adolphe Email: #### Prolato Clinical Research Center Recruiting Houston,Texas,77054,United States ###### Romeo Parada Phone: [+1 832 338 9118]() Email: ###### Sreedhar Mandayam #### Washington University in St Louis Recruiting St Louis,Missouri,63110,United States ###### Michelle Bloom Phone: [+1 314 362 5298]() Email: ###### Tingting Li #### University Of Cincinnati Recruiting Cincinnati,Ohio,45267,United States ###### Indraneel Reddy ###### Leksi Travitz Email: #### OHSU Dept of Nephrology Recruiting Portland,Oregon,97239,United States ###### Madison Stanaway Phone: [+1 503 494 4233]() Email: ###### Rupali Avasare #### UT Southwestern Medical Center Recruiting Dallas,Texas,75235,United States ###### Jyothsna Gattineni ###### Melaku Lemma Email: #### MUSC Health Lancaster Med Ctr Recruiting Lancaster,South Carolina,29720,United States ###### Darann Wiegand Email: ###### Prince Anand #### Emory University School of Medicine-Winship Cancer Institute Recruiting Atlanta,Georgia,30322,United States ###### Heather Jung Email: ###### Laurence Larry Greenbaum Vietnam #### Novartis Investigative Site Recruiting Ho Chi Minh City,700000,Vietnam ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: [](mailto:) #### Novartis Pharmaceuticals Phone: [ 1-888-669-6682](tel:1-888-669-6682) Email: